Transcriptome Analysis with B-ALL and MLN-TK

20. December 2022

Whole transcriptome sequencing (WTS) is becoming increasingly important in the routine diagnostics of leukemia. In addition to the holistic detection of fusion transcripts, transcriptome analysis also makes it possible to determine subtype-specific expression profiles for more accurate stratification of patients. Thus, according to the new WHO classification (5th edition), some subtypes can only be determined by analyzing gene expression profiles. Therefore, for both B-ALL and MLN-TK, we have included transcriptome analysis in our routine workflows and offer it accordingly.


Transcriptome Analysis with B-ALL

B-ALL is primarily classified into its subtypes genetically by determining copy number alterations of individual chromosomes or whole chromosome sets and by detecting translocations and corresponding fusion transcripts. In addition, we also know of groups where no known fusions are detectable in the patients, yet their expression profile is hardly distinguishable from that of patients with defined translocations – these include BCR::ABL1-like or ETV6::RUNX1-like B-ALL. The ability to detect fusion transcripts and create expression profiles is a strength of transcriptome analysis, which is why we have started using it to determine B-ALL subtypes. After whole transcriptome sequencing, we use an algorithm trained via machine learning that can distinguish and classify 18 different B-ALL subtypes based on their expression profiles (ALLSorts, Schmidt B et al., Blood Adv. 2022 Jul 26;6(14):4093-4097). Only the subgroups with deviating numbers of chromosomes (hyper/hypodiploid) are not reliably detected by this method. In contrast, however, other groups, such as BCR::ABL1-like, ETV6::RUNX1-like, and DUX4 rearrangements, can only be detected using such a method.


Transcriptome Analysis with MLN-TK

The newly named entity myeloid/lymphoid neoplasia with eosinophilia and tyrosine kinase gene fusion bears in its very name the diagnostic criterion of detection of a tyrosine kinase gene fusion. While the most commonly detected fusions are FIP1L1::PDGFRA, ETV6::PDGFRB, ZMYM2::FGFR1, and also PCM1::JAK2, other tyrosine kinase gene fusions can also occur in rare cases. Due to its therapeutic relevance, when MLN-TK is suspected, an extended and broad-based screening – after ruling out known fusions – is recommended as part of a stepwise diagnostic process. The advantage of transcriptome analysis is being able to simultaneously determine aberrant tyrosine kinase expressions as well as rare tyrosine kinase gene fusions along with known ones. The sequence of a detected fusion can also be used to identify whether it occurred within the reading frame and whether it leads to a functional tyrosine kinase, which then serves as a potential target for corresponding inhibitors.

 

Transcriptome analysis is on our request form as a diagnostic method for both B-ALL and MLN-TK.

The author

»Do you have questions regarding this article or do you need further information? Please send me an e-mail.«

Dr. rer. nat. Manja Meggendorfer, MBA

Biologist, Dipl.
Head of business unit Diagnostic Genetics
Head of Molecular genetics

T: +49 89 99017-355

You might also be interested in

Prof. Dr. med. Dr. phil. Torsten Haferlach
at 19.12.2024

Growth, Progress, and Gratitude: 2024 Annual Review

MLL MVZ looks back on a year full of milestones. In our year in review, we provide information on new diagnostic methods, personalised patient care, the nationwide specimen transport service and other highlights from 2024.

Read more

Dr. rer. nat. Katharina Hörst
at 18.12.2024

The MLL at the 66th ASH Annual Meeting & Exposition – A Recap

The 66th Annual Meeting & Exposition of the American Society of Hematology (ASH) was held in San Diego, California from 7 to 10 December. In this article, we take a look at the highlights of the seven papers presented by MLL at this year's ASH.

Read more

Julia Hennig
at 18.12.2024

KIM-Mail: A Secure Communication Channel for Medical Data

Conventional e-mail is not suitable for transmitting sensitive patient data. We are also interested in replacing analogue methods of transmitting reports, especially fax. This is why we have established the use of KIM-Mail in addition to our findings portal.

Read more